MedTrace Logo

Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

NCT00003433 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.

Conditions

Interventions

BIOLOGICAL

carcinoembryonic antigen RNA-pulsed DC cancer vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Duke Cancer Institute

    lead OTHER

Principal Investigators

  • Herbert K. Lyerly, MD · Duke Cancer Institute

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Completion
2003-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003433 on ClinicalTrials.gov